Last reviewed · How we verify

LEANDRO CABRAL ZACHARIAS — Portfolio Competitive Intelligence Brief

LEANDRO CABRAL ZACHARIAS pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Intravitreal ranibizumab Intravitreal ranibizumab marketed VEGF-A inhibitor (monoclonal antibody fragment) VEGF-A (Vascular Endothelial Growth Factor A) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Greater Houston Retina Research · 1 shared drug class
  4. Hoffmann-La Roche · 1 shared drug class
  5. Medical University of Vienna · 1 shared drug class
  6. Retinal Consultants of Arizona · 1 shared drug class
  7. Samsung Bioepis Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for LEANDRO CABRAL ZACHARIAS:

Cite this brief

Drug Landscape (2026). LEANDRO CABRAL ZACHARIAS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/leandro-cabral-zacharias. Accessed 2026-05-16.

Related